- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Synthesis of a PCSK9 Inhibitor ; volume:14 ; number:03 ; year:2018 ; pages:0223
Synfacts ; 14, Heft 03 (2018), 0223
- DOI
-
10.1055/s-0037-1609112
- URN
-
urn:nbn:de:101:1-2018092909453398340453
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Ähnliche Objekte (12)
PCSK9 inhibitors in the prevention of cardiovascular disease
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Berberine : Ins and outs of a nature-made PCSK9 inhibitor
Evolocumab (Repatha) - PCSK9-Inhibitor : kardiovaskuläre Risikioreduktion durch konsequente Lipidsenkung
PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes
PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
Chronische Effekte von PCSK9-Inhibitoren auf die Makro- und Mikrostrombahn
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?
Gene Therapy Targeting PCSK9
PCSK9 inhibitors in the prevention of cardiovascular disease
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Berberine : Ins and outs of a nature-made PCSK9 inhibitor
Evolocumab (Repatha) - PCSK9-Inhibitor : kardiovaskuläre Risikioreduktion durch konsequente Lipidsenkung
PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes
PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
Chronische Effekte von PCSK9-Inhibitoren auf die Makro- und Mikrostrombahn
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?
Gene Therapy Targeting PCSK9
PCSK9 inhibitors in the prevention of cardiovascular disease
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Berberine : Ins and outs of a nature-made PCSK9 inhibitor
Evolocumab (Repatha) - PCSK9-Inhibitor : kardiovaskuläre Risikioreduktion durch konsequente Lipidsenkung
PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes
PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
Chronische Effekte von PCSK9-Inhibitoren auf die Makro- und Mikrostrombahn
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?